Search Names & Symbols

With personal love and passion we work alone and analyze our favorite shares. May not be many, but they are worth it.

The best online stock broker. Open an account today and start earning up to $1000 of IBKR Stock !

Wednesday, August 31, 2022

Monday, August 29, 2022

Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian

 

The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke events in patients with atrial fibrillation as well as patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack involving up to 30,000 patients / Bayer drives the development of its FXIa inhibitor, with the goal of offering a potential new class of antithrombotics for improved outcomes for patients using selective coagulation modulation
 

Saturday, August 27, 2022

Tuesday, August 9, 2022

DISCLAIMER:

The financial and technical analycies presented on this website have not been performed by an Investment Services Company, nor have they been compiled by a certified analyst . It is simply a display and presentation of public data of Greek and foreign shares with informative and entertaining character.

My opinion on the shares of our site

Τhe situation of the stock market